SE Limited's DFS unit posts 60% revenue growth as its loan book nears $8B, fueled by strong demand, rising adoption and broader product expansion.
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback